We found that most cell-cycle-related genes were overexpressed in supratentorial and posterior fossa ependymomas, particularly cyclin D1 and CDK4, which can serve as actionable therapeutic targets. The gene discussed is CCND1; the disease is posterior fossa ependymoma.